Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Personalized Infliximab Induction Strategy in Crohn's Disease
NCT04974099Phase 3Terminated
- Sponsor
- Cincinnati Children's Hospital Medical Center
- Start
- Oct 2021
- Primary completion
- Aug 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of infliximab in Crohn's disease, sponsored by Cincinnati Children's Hospital Medical Center. Primary endpoints: Safety Data for Optimal Dosing Strategy at 10 months, Enrollment Feasibility at 10 months and 5 more. Started Oct 2021; status: terminated.
02
Drugs
infliximab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT04974099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04974099.